Literature DB >> 22964946

Risks for infection in patients with myelodysplasia and acute leukemia.

Livio Pagano1, Morena Caira.   

Abstract

PURPOSE OF REVIEW: The aim of the present review is to analyze the main parameters that may influence the onset of bacterial, fungal and viral infections in patients with myelodysplastic syndromes, acute myeloid leukemia and acute lymphoid leukemia. RECENT
FINDINGS: The identification of factors influencing the onset of infections in high-risk patients is becoming one of the most important strategies to identify those patients who would really benefit from prophylactic and timely treatment. During the past few years several studies have been conducted to evaluate the impact of risk factors that may influence both the onset and the outcome of infections. The role of some of them is well defined (i.e. neutropenia, central venous catheters), whereas other factors are now emerging as new possible causative factors (i.e. iron overload, hospitalization).
SUMMARY: Many factors have to be considered when evaluating the infectious risk in hematological patients. In current clinical practice the good knowledge of these factors may favor a better management of infectious risk, with a reduction of mortality rate.

Entities:  

Mesh:

Year:  2012        PMID: 22964946     DOI: 10.1097/QCO.0b013e328358b000

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  9 in total

1.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

Review 2.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

3.  Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.

Authors:  Daniel A Pollyea; Chelsea Harris; Jennifer L Rabe; Brenna R Hedin; Lesly De Arras; Sigrid Katz; Emily Wheeler; Rafael Bejar; Matthew J Walter; Craig T Jordan; Eric M Pietras; Scott Alper
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

4.  Focused extracorporeal shock wave for osteonecrosis of the femoral head with leukemia after allo-HSCT: a case series.

Authors:  W Sun; F Gao; W Guo; B Wang; Z Li; L Cheng; W Wang
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

5.  Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.

Authors:  Rafael Cámara; Irmina Gozalbo; Manuel Jurado; Jaime Sanz; Belén Aragón; Santiago Grau
Journal:  Adv Ther       Date:  2017-08-14       Impact factor: 3.845

6.  SARS-Cov-2 pneumonia and concurrent myelodysplasia complicated by Pseudomonas aeruginosa over-infection.

Authors:  Aldo Pezzuto; Antonella Tammaro; Giuseppe Tonini; Giulia Conforti; Francesca Falangone; Valerio Spuntarelli; Antonella Teggi; Alfredo Pennica
Journal:  J Virol Methods       Date:  2021-12-10       Impact factor: 2.014

7.  Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia.

Authors:  Lorenza Bellusci; Gabrielle Grubbs; Pragya Srivastava; Michael J Nemeth; Elizabeth A Griffiths; Hana Golding; Surender Khurana
Journal:  Blood       Date:  2022-05-05       Impact factor: 25.476

Review 8.  Emerging roles of spliceosome in cancer and immunity.

Authors:  Hui Yang; Bruce Beutler; Duanwu Zhang
Journal:  Protein Cell       Date:  2021-07-01       Impact factor: 15.328

Review 9.  Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy.

Authors:  Giuseppe Leone; Livio Pagano
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-07-01       Impact factor: 3.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.